Financial Ratios

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE1087.10-27.8 (-2.49 %)
PREV CLOSE ( ) 1114.90
OPEN PRICE ( ) 1100.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 75136
TODAY'S LOW / HIGH ( )1079.00 1104.20
52 WK LOW / HIGH ( )575.1 1177
NSE1087.05-27.45 (-2.46 %)
PREV CLOSE( ) 1114.50
OPEN PRICE ( ) 1109.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1087.05 (1075)
VOLUME 1304443
TODAY'S LOW / HIGH( ) 1079.00 1109.00
52 WK LOW / HIGH ( )576.15 1177.1
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)21.0024.8353.1332.0326.11
   CEPS(Rs)28.4331.9261.4640.1133.16
   DPS(Rs)3.009.004.003.002.50
   Book NAV/Share(Rs)305.75292.15271.80222.78193.73
   Tax Rate(%)23.7811.1625.7620.8122.14
Margin Ratios
   Core EBITDA Margin(%)13.4312.8225.9520.1119.56
   EBIT Margin(%)13.4214.5826.5919.4817.83
   Pre Tax Margin(%)12.5314.4326.4117.6715.95
   PAT Margin (%)9.5512.8219.6113.9912.42
   Cash Profit Margin (%)12.9316.4822.6817.5215.78
Performance Ratios
   ROA(%)4.575.8214.269.969.02
   ROE(%)7.028.8121.4915.3814.34
   ROCE(%)8.448.5223.0316.0114.85
   Asset Turnover(x)0.480.450.730.710.73
   Sales/Fixed Asset(x)2.161.832.472.312.53
   Working Capital/Sales(x)4.222.012.852.733.35
Efficiency Ratios
   Fixed Capital/Sales(x)0.460.550.410.430.40
   Receivable days120.87159.20134.65149.89143.76
   Inventory Days105.97131.81105.77113.34109.38
   Payable days113.35128.68113.22118.72115.57
Valuation Parameters
   PER(x)24.6726.9416.5912.8930.10
   PCE(x)18.2220.9614.3410.3023.70
   Price/Book(x)1.692.293.241.854.06
   Yield(%)0.581.350.450.730.32
   EV/Net Sales(x)2.693.633.492.084.12
   EV/Core EBITDA(x)15.8719.1011.729.0219.36
   EV/EBIT(x)19.8724.7613.0810.6523.00
   EV/CE(x)1.231.582.291.423.18
   M Cap / Sales2.373.473.261.813.76
Growth Ratio
   Net Sales Growth(%)13.33-28.6718.359.0819.36
   Core EBITDA Growth(%)0.95-54.4752.5818.33-5.17
   EBIT Growth(%)4.53-60.8161.5419.03-8.36
   PAT Growth(%)-15.42-53.2765.8622.69-15.61
   EPS Growth(%)-15.42-53.2765.8622.69-15.61
Financial Stability Ratios
   Total Debt/Equity(x)0.230.110.250.290.40
   Current Ratio(x)1.442.351.831.771.55
   Quick Ratio(x)0.851.551.111.090.96
   Interest Cover(x)15.0497.66147.2010.749.51
   Total Debt/Mcap(x)0.140.050.080.150.10

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.